20n Bio
20n Bio is a VC-backed startup dedicated to discovering cyclic peptides for therapeutic use. Based in the Greater Philadelphia region, their mission is to address unmet medical needs by leveraging high-throughput screening and chemical optimization to develop peptide drugs across various therapeutic areas. They have developed a proprietary platform capable of screening trillions of peptides to identify potent candidates and have built partnerships with pharmaceutical and biotech companies.
Industries
Nr. of Employees
small (1-50)
Products
Proprietary peptide discovery platform
An integrated discovery platform capable of screening ultra-large peptide libraries and supporting downstream chemical optimization to identify high-affinity peptide candidates.
Proprietary peptide discovery platform
An integrated discovery platform capable of screening ultra-large peptide libraries and supporting downstream chemical optimization to identify high-affinity peptide candidates.
Services
Licensing of early discovery hits and collaborative discovery projects with pharmaceutical and biotechnology companies.
Tailored discovery services combining ultra-large library screening and chemical optimization to generate candidate peptides for specified targets or modalities.
Licensing of early discovery hits and collaborative discovery projects with pharmaceutical and biotechnology companies.
Tailored discovery services combining ultra-large library screening and chemical optimization to generate candidate peptides for specified targets or modalities.
Expertise Areas
- Peptide discovery
- High-throughput screening and selection
- Computational protein/peptide design
- Lead optimization and medicinal chemistry for peptides
Key Technologies
- Ultra-large peptide libraries
- Cyclic peptide discovery
- High-throughput screening
- Computational design algorithms for peptides/proteins
News & Updates
May 16, 2025, 20n Bio joins Bayer Co.lab.
Jan 31, 2024: 20n Bio appoints Linghang Zhuang, Ph.D., as President, to lead the discovery of cyclic peptide drugs.
Dec 17, 2021: 20n Bio raises $3.3 Million in Series Seed Funding.
May 16, 2025, 20n Bio joins Bayer Co.lab.
Jan 31, 2024: 20n Bio appoints Linghang Zhuang, Ph.D., as President, to lead the discovery of cyclic peptide drugs.
Dec 17, 2021: 20n Bio raises $3.3 Million in Series Seed Funding.